{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:59:38Z","timestamp":1775908778178,"version":"3.50.1"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This study aimed to evaluate the efficacy of immunotherapy combined with anti-angiogenic therapy for non-small cell lung cancer (NSCLC) with brain metastasis (BM) and negative driver genes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This observational prospective study was conducted using the clinical data of 34 patients with NSCLC and BM, including 24 patients who received immunotherapy combined with anti-angiogenic therapy and 10 control patients using oral anlotinib upon the first- to fourth-line treatment failure or refusing to continue chemotherapy between June 2017 and August 2022. Efficacy was evaluated using progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 24 patients treated with immunotherapy combined with anti-angiogenic therapy, 17 had a partial response, six had stable disease, and one had progressive disease. The ORR and DCR of patients receiving immunotherapy combined with anti-angiogenic therapy were 70.8% and 95.8%, respectively. The median PFS of immunotherapy combined with anti-angiogenic treatment was significantly longer than that of oral anlotinib (18.0\n                      <jats:italic>vs<\/jats:italic>\n                      . 4 months, log-rank test, p &amp;lt; 0.0001), indicating that immunotherapy combined with anti-angiogenic therapy can substantially improve the treatment efficacy for NSCLC with BM and negative driver genes. Adverse reactions mainly included rash in one case and hypothyroidism in one case, but did not involve myocardial damage or liver and kidney function damage.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Immunotherapy combined with anti-angiogenic therapy in patients with recurrent or refractory NSCLC and BM driven by negative genes has yielded promising but preliminary findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>www.chictr.org.cn<\/jats:ext-link>\n                      , identifier ChiCTR1800017499\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1684759","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T05:20:39Z","timestamp":1764739239000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Combination immunotherapy and anti-angiogenic therapy shows promising efficacy in NSCLC patients with recurrent or refractory brain metastases and negative driver genes"],"prefix":"10.3389","volume":"16","author":[{"given":"Liwei","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinduo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caijuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengfei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jncc.2022.02.002","article-title":"Cancer incidence and mortality in China, 2016","volume":"2","author":"Zheng","year":"2022","journal-title":"J Natl Cancer Cent"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-022-2240-6","article-title":"Overview and countermeasures of cancer burden in China","volume":"66","author":"Wang","year":"2023","journal-title":"Sci China Life Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.03.006","article-title":"Systemic treatment of brain metastases in non-small cell lung cancer","volume":"132","author":"Page","year":"2020","journal-title":"Eur J Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3390\/ijms22020593","article-title":"Treatment of brain metastases of non-small cell lung carcinoma","volume":"22","author":"Rybarczyk-Kasiuchnicz","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.04.014","article-title":"Immunotherapy as single treatment for patients with NSCLC with brain metastases: A systematic review and meta-analysis-the META-L-BRAIN study","volume":"16","author":"Teixeira Loiola de Alencar","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2004.07.968","article-title":"Treatment of brain metastases from non-small-cell lung cancer (NSCLC): radiotherapy","author":"Zabel","year":"2004","journal-title":"Lung Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31391-5","article-title":"Whole brain radiotherapy in patients with NSCLC and brain metastases","volume":"388","author":"Pechoux","year":"2016","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"13173","DOI":"10.1038\/s41598-023-40235-0","article-title":"Effect of whole-brain radiotherapy with platinum-based chemotherapy in non-small cell lung cancer patients with multiple metastases including brain metastases","volume":"13","author":"Ryu","year":"2023","journal-title":"Sci Rep"},{"key":"B9","doi-asserted-by":"publisher","first-page":"8267","DOI":"10.1038\/s41598-018-26636-6","article-title":"Metastatic brain tumors disrupt the blood-brain barrier and alter lipid metabolism by inhibiting expression of the endothelial cell fatty acid transporter mfsd2a","volume":"8","author":"Tiwary","year":"2018","journal-title":"Sci Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1186\/s12935-021-02263-6","article-title":"The structure of blood-tumor barrier and distribution of chemotherapeutic drugs in non-small cell lung cancer brain metastases","volume":"21","author":"Ye","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1297988","article-title":"Brain metastases and lung cancer: molecular biology, natural history, prediction of response and efficacy of immunotherapy","volume":"14","author":"Sereno","year":"2023","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e4401","DOI":"10.1097\/MD.0000000000004401","article-title":"Pemetrexed\/cisplatin as first-line chemotherapy for advanced lung cancer with brain metastases: A case report and literature review","volume":"95","author":"He","year":"2016","journal-title":"Med (Baltimore)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nos004","article-title":"Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma","volume":"14","author":"Bailon","year":"2012","journal-title":"Neuro Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2016.03.098","article-title":"Phase II study of high-dose pemetrexed plus cisplatin as first-line chemotherapy in the treatment of patients with brain metastases from lung adenocarcinoma","volume":"99","author":"He","year":"2017","journal-title":"World Neurosurg"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2003.n.008","article-title":"Docetaxel versus docetaxel\/cisplatin in patients with advanced non-small-cell lung cancer: preliminary analysis of a multicenter, randomized phase III study","volume":"4","author":"Georgoulias","year":"2003","journal-title":"Clin Lung Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0013","article-title":"NCCN guidelines insights: non-small cell lung cancer, version 2.2021","volume":"19","author":"Ettinger","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0020","article-title":"NCCN guidelines\u00ae Insights: non-small cell lung cancer, version 2.2023","volume":"21","author":"Ettinger","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.875488","article-title":"The long-term and short-term efficacy of immunotherapy in non-small cell lung cancer patients with brain metastases: A systematic review and meta-analysis","volume":"13","author":"Chu","year":"2022","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.02.009","article-title":"Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity","volume":"86","author":"Anderson","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12964-022-00838-y","article-title":"Cancer combination therapies by angiogenesis inhibitors; a comprehensive review","volume":"20","author":"Ansari","year":"2022","journal-title":"Cell Commun Signal"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0838","article-title":"The impact of anlotinib on brain metastases of non-small cell lung cancer: post hoc analysis of a phase III randomized control trial (ALTER0303)","volume":"25","author":"Jiang","year":"2020","journal-title":"Oncologist"},{"key":"B23","doi-asserted-by":"publisher","first-page":"7298192","DOI":"10.1155\/2022\/7298192","article-title":"Clinical study on the efficacy of bevacizumab in combination with pembrolizumab on cellular immune function in the treatment of driver gene-negative stage IV lung adenocarcinoma","volume":"2022","author":"Gong","year":"2022","journal-title":"J Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.835","article-title":"711P Sintilimab combined with bevacizumab biosimilar as a conversion therapy in potentially resectable intermediate stage hepatocellular carcinoma (HCC): A phase II trial","volume":"33","author":"Sun","year":"2022","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12962-023-00435-x","article-title":"Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China","volume":"21","author":"Gong","year":"2023","journal-title":"Cost Eff Resour Alloc"},{"key":"B26","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1186\/s12885-022-10045-0","article-title":"Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00382-5","article-title":"Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial","volume":"23","author":"Lu","year":"2022","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3892\/ol.2025.15180","article-title":"Research progress of anti-angiogenic therapy combined with immunotherapy and radiotherapy for the treatment of brain metastases in non-small cell lung cancer (Review)","volume":"30","author":"Li","year":"2025","journal-title":"Oncol Lett"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13600","article-title":"Duration of immunotherapy in patients with advanced lung adenocarcinoma with negative driver genes: case report and literature review","volume":"11","author":"Shan","year":"2020","journal-title":"Thorac Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30458-9","article-title":"Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a\/b trial","volume":"20","author":"Herbst","year":"2019","journal-title":"Lancet Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1634\/theoncologist.2018-0044","article-title":"Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, phase I trial (JVDF)","volume":"23","author":"Arkenau","year":"2018","journal-title":"Oncologist"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/s41467-025-57184-z","article-title":"Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial","volume":"16","author":"Yi","year":"2025","journal-title":"Nat Commun"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1186\/s12885-024-13264-9","article-title":"Efficacy and safety of combining anti-angiogenic therapy, radiotherapy, and PD-1 inhibitors in patients with driver gene-negative non-small cell lung cancer brain metastases: a retrospective study","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01956","article-title":"Anti-angiogenic agents in combination with immune checkpoint inhibitors: A promising strategy for cancer treatment","volume":"11","author":"Song","year":"2020","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"101948","DOI":"10.1016\/j.ctrv.2019.101948","article-title":"Adjuvant chemotherapy for rectal cancer: Current evidence and recommendations for clinical practice","volume":"83","author":"Bregni","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"B37","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1186\/s12885-019-6054-x","article-title":"Patient preferences of chemotherapy treatment options and tolerance of chemotherapy side effects in advanced stage lung cancer","volume":"19","author":"Islam","year":"2019","journal-title":"BMC Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14664","article-title":"Immunotherapy combined with chemotherapy versus chemotherapy alone as the first-line treatment of PD-L1-negative and driver-gene-negative advanced nonsquamous non-small-cell lung cancer: An updated systematic review and meta-analysis","volume":"13","author":"Chai","year":"2022","journal-title":"Thorac Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","volume":"26","author":"Pignon","year":"2008","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2008.s.010","article-title":"Emerging safety data for bevacizumab in advanced non-small-cell lung cancer","author":"Hirsh","year":"2008","journal-title":"Clin Lung Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000776","article-title":"Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study","volume":"80","author":"Zhu","year":"2024","journal-title":"Hepatology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.689132","article-title":"The combination of immune checkpoint blockade and angiogenesis inhibitors in the treatment of advanced non-small cell lung cancer","volume":"12","author":"Ren","year":"2021","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"104883","DOI":"10.1016\/j.critrevonc.2025.104883","article-title":"Combination of immune checkpoint inhibitors and anti-angiogenic agents: An emerging strategy for cancer therapy","volume":"215","author":"Li","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.3056","article-title":"A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results","volume":"34","author":"Herbst","year":"2016","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/j.ijrobp.2014.08.206","article-title":"Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) maintenance as monotherapy or in combination with bevacizumab (BEV) for non-small cell lung cancer (NSCLC) previously treated with chemotherapy: metastatic non-small cell lung cancer","volume":"90","author":"Rizvi","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1684759\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T05:20:40Z","timestamp":1764739240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1684759\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2025.1684759"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1684759","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"article-number":"1684759"}}